Response to Dr Urata’s Letter to the Editor of Modern Rheumatology regarding a study of “Treatment of rheumatoid arthritis after regression of lymphoproliferative disorders”
Modern Rheumatology · 2023
DOI: 10.1093/mr/roac135 ↗Kurz gefasst
Kommentar in der Zeitschrift Modern Rheumatology, 2023. Verfasst von Kazuhisa Nakano. Beteiligte Einrichtung: The Department of Rheumatology, Kawasaki Medical School, Kurashiki, Japan. Hauptthemen laut MEDLINE: Rheumatology, Arthritis, Rheumatoid, Lymphoproliferative Disorders. Die Arbeit nennt 2 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Department of Rheumatology, Kawasaki Medical School, Kurashiki, Japan.
- The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
- Working Group on the Rheumatoid Arthritis-associated Lymphoproliferative Disorders of the Japan College of Rheumatology.
Zitieren
APA
Nakano, K. (2023). Response to Dr Urata’s Letter to the Editor of Modern Rheumatology regarding a study of “Treatment of rheumatoid arthritis after regression of lymphoproliferative disorders”. Modern Rheumatology. https://doi.org/10.1093/mr/roac135
Vancouver
Nakano K. Response to Dr Urata’s Letter to the Editor of Modern Rheumatology regarding a study of “Treatment of rheumatoid arthritis after regression of lymphoproliferative disorders”. Modern Rheumatology. 2023. doi:10.1093/mr/roac135
BibTeX
@article{Nakano2023,
author = {Nakano, Kazuhisa},
title = {Response to Dr Urata’s Letter to the Editor of Modern Rheumatology regarding a study of “Treatment of rheumatoid arthritis after regression of lymphoproliferative disorders”},
journal = {Modern Rheumatology},
year = {2023},
doi = {10.1093/mr/roac135}
}
EUVIMED